Foamy Microglia Drive MS Progression Through Disrupted Lipid Metabolism
Scientists identify a rogue immune cell population fueling multiple sclerosis progression — and a promising drug target to stop it.
Summary
Researchers studying postmortem brain tissue from multiple sclerosis patients discovered a distinct population of lipid-laden 'foamy' immune cells called GPNMB+ microglia that appear to drive disease progression in secondary progressive MS. These cells accumulate in expanding lesions and are marked by disrupted lipid processing, cellular stress, and increased immune activity. An enzyme called MAGL, found in high levels in these lesions, emerged as a potential treatment target — blocking it in mice reduced lesion damage and immune cell buildup. Oxylipin molecules detected in cerebrospinal fluid may also serve as biomarkers for tracking disease progression. The findings open a new window into how lipid biology shapes chronic MS and suggest that targeting foamy microglia could be a viable strategy for progressive forms of the disease.
Detailed Summary
Multiple sclerosis is a debilitating neurological condition in which the immune system attacks the brain's protective myelin sheath, causing lesions that accumulate over time and lead to irreversible disability. While treatments exist for relapsing forms of MS, progressive MS remains far harder to treat, and the cellular mechanisms driving ongoing lesion expansion are poorly understood. This study addresses that gap.
Researchers from Leiden University, the Netherlands Institute for Neuroscience, and Roche analyzed postmortem human MS brain tissue using an unusually comprehensive multi-omics approach — combining lipidomics, transcriptomics, proteomics, chemical proteomics, and histology. Their goal was to understand what distinguishes lesions that continue to expand from those that stabilize.
The team identified a specific population of foamy GPNMB+ microglia and macrophages concentrated in actively expanding lesions from secondary progressive MS patients. These cells displayed hallmarks of lysosomal stress, heightened phagocytosis, and antigen presentation, yet lacked the classical inflammatory signatures typically associated with tissue damage. The lesions were enriched with oxylipins, bismonoacylglycerolphosphates, and cholesterol esters, pointing to a fundamental disruption in lipid metabolism as a driver of chronic pathology.
A lipid-metabolizing enzyme called monoacylglycerol lipase (MAGL) was found to be highly enriched in these foamy microglial lesions. Crucially, inhibiting MAGL in a mouse demyelination model promoted lesion recovery and reduced microgliosis, validating it as a therapeutic target. Additionally, oxylipins measured in cerebrospinal fluid correlated with the proportion of foamy lesions in postmortem tissue, raising the possibility of a non-invasive biomarker for progressive disease monitoring.
The study is limited by its postmortem human tissue design and the use of a mouse model for mechanistic validation. Nonetheless, it provides a compelling mechanistic link between lipid dysregulation, immune cell dysfunction, and MS progression — with clear translational implications.
Key Findings
- GPNMB+ foamy microglia in expanding MS lesions show lysosomal stress and heightened antigen presentation without classical inflammation.
- Lesions with foamy microglia are enriched with oxylipins and cholesterol esters, indicating disrupted lipid metabolism.
- MAGL enzyme inhibition reduced lesion damage and microgliosis in a mouse demyelination model, identifying a new drug target.
- CSF oxylipins correlate with the proportion of foamy lesions, suggesting a potential biomarker for progressive MS.
- B cell infiltration and IgG1 levels were elevated in foamy microglial lesions, hinting at an adaptive immune component.
Methodology
The study used postmortem human MS brain tissue analyzed through integrated lipidomics, transcriptomics, proteomics, chemical proteomics, and histology. A mouse model of demyelination was used to test MAGL inhibition as a therapeutic strategy. Cerebrospinal fluid samples were analyzed to explore oxylipin biomarker potential.
Study Limitations
This summary is based on the abstract only, as the full text was not accessible. The mechanistic findings rely on postmortem tissue, which limits causal inference in humans. Mouse model results may not fully translate to human progressive MS biology.
Enjoyed this summary?
Get the latest longevity research delivered to your inbox every week.